Copanlisib+Rituximab Shows Promise for Some Lymphomas

According to the American Society of Hematology (ASH), findings from phase III of the CHRONOS-3 trial testing a combination therapy using copanlisib and rituximab reduced the risk of progression or death by 48% compared with rituximab alone. The study was open to participants who had relapsed Indolent B-cell Non-Hodgkin’s Lymphoma, including follicular lymphoma, small lymphocytic…… Continue reading Copanlisib+Rituximab Shows Promise for Some Lymphomas

Lacutamab Clinical Trial for Certain CTCL Patients

Innate Pharma has recently announced phase 2 of a clinical trial dubbed TELLOMAK regarding the investigative drug lacutamab (IPH4102), an anti-KIR3DL2 monoclonal antibody, alone or in combination with chemo. The focus of this study is the treatment of patients with the rare cutaneous t-cell lymphoma (CTCL) Mycosis Fungoides and it’s systemic comparable Sézary Syndrome. The…… Continue reading Lacutamab Clinical Trial for Certain CTCL Patients

TIL Therapy Showing Promise

Tumor Infiltrating Lymphocyte (TIL) therapy is reportedly showing promise as an immunotherapy treatment. What the heck is a tumor infiltrating lymphocyte? It’s pretty much what it sounds like, a white blood cell that has managed to make it’s way into a cancer tumor. Why is that interesting? Well, in part because many cancers are slick…… Continue reading TIL Therapy Showing Promise